Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort
Die Pharmazie · 01.10.2024 · 79 (9)
DOI: 10.31083/ph.2024.4570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 01.10.2024. Verfasst von I. Conic und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Background
The incorporation of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has redefined therapeutic strategies for advanced ovarian cancer. This study evaluates the efficacy of bevacizumab combined with standard chemotherapy by comparing progression-free survival (PFS) and overall survival (OS) outcomes with a historical cohort of patients treated with standard chemotherapy alone.
Methods
We conducted an analysis of 71 patients with advanced epithelial ovarian cancer treated at the University Clinical Center in Niš, Serbia, from April 2017 to March 2023. All patients received standard chemotherapy paired with bevacizumab and were monitored for progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier estimates. Subgroup analyses were performed based on age, ECOG performance status, presence of metastases, and pleural effusion. Additionally, a historical cohort of 30 patients treated with standard chemotherapy alone was used for comparison, and Cox regression analysis was conducted to identify factors influencing treatment outcomes.
Results
The study findings indicate significant improvements in median PFS (20 months vs. 15 months) and OS (58 months vs. an undetermined upper limit) compared to the historical cohort. Subgroup analysis of the bevacizumab-treated group revealed that younger patients (
Zitieren
APA
Conic, I., Nedovic, B., Zivadinovic, R., Zivadinovic, R., Petric, A., Stojnev, S., Petkovic, I., Krtinic, D., & Radic, M. (2024). Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort. Die Pharmazie, 79(9). https://doi.org/10.31083/ph.2024.4570
Vancouver
Conic I, Nedovic B, Zivadinovic R, Zivadinovic R, Petric A, Stojnev S, et al. Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort. Die Pharmazie. 2024;79(9). doi:10.31083/ph.2024.4570
BibTeX
@article{Conic2024,
author = {Conic, I. and Nedovic, B. and Zivadinovic, R. and Zivadinovic, R. and Petric, A. and Stojnev, S. and Petkovic, I. and Krtinic, D. and Radic, M.},
title = {Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort},
journal = {Die Pharmazie},
year = {2024},
volume = {79},
number = {9},
doi = {10.31083/ph.2024.4570}
}
EUVIMED